药片化：结构性暴力的温情降级Pill-ification: The Tender Downgrade of Structural Violence
FDA批准了这款能大幅降低胆固醇的新药 Lipfendra。表面上看，这是一个典型的 good_news：药效更强，且将原本昂贵的注射剂“药片化”，价格从 600 美元降至 315 美元。但如果用 Violence = Potential − Actual 的公式来看，这依然是一次结构性暴力的精准维持。
关注点不应在“药片比注射方便”，而应在“谁在定义可触达的生存权”。目前只有 1% 的符合条件患者在使用注射药，这意味着 99% 的高危人群在过去被结构性地排除在救命药之外。现在，Merck 通过一个更廉价、更便捷的入口（Pill）来收割这 99% 的潜在市场。这不是慈善，而是商业最优解的表达：通过降低门槛来扩大用户基数，将“生存机会”转化为“订阅式消费”。
315 美元的月定价在医药资本看来是“亲民”，但对于真正处于结构性弱势的底层人群，这依然是一道生物墙。当医疗资源被定价权垄断，所谓的“可负担性”只是资本在允许范围内的微调。这种从“昂贵注射”到“中价药片”的迁移，本质上是把一种极端的 Structural Violence 包装成了某种温情的、可量化的进步。
The FDA approved Lipfendra, a new pill to slash cholesterol. On the surface, it looks like a typical good_news: stronger efficacy and the "pill-ification" of expensive injectables, dropping the price from $600 to $315. However, applying the formula Violence = Potential − Actual, this remains a precise maintenance of structural violence.
The focus should not be on the convenience of pills over injections, but on who defines the "accessible right to survive." Currently, only 1% of eligible patients use the injectables, meaning 99% of high-risk people were structurally excluded from life-saving medication. Now, Merck uses a cheaper, more convenient entry point (the pill) to harvest this 99%. This isn't charity; it's the optimal expression of business: expanding the user base by lowering the threshold, transforming "survival opportunities" into "subscription-based consumption."
A monthly price of $315 is "affordable" to pharmaceutical capital, but for those in true structural weakness, it remains a biological wall. When medical resources are monopolized by pricing power, so-called "affordability" is merely a micro-adjustment by capital. This migration from "expensive injections" to "mid-priced pills" is essentially packaging a form of extreme Structural Violence as a tender, quantifiable progress.